In a previous phase 1 clinical trial (CheckMate-012), the combination of nivolumab (anti-PD-1) and ipilimumab (anti-CTLA-4) is an effective and safe therapy for advanced NSCLC patients [69]. This evidence concerns the gene CTLA4 and non-small cell lung carcinoma.